| Date | Title | Description |
| 07.01.2025 | Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment | TAMPA, Fla., Jan. 7, 2025 /PRNewswire/ -- Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting B... |
| 22.04.2024 | Can drinking cold water trigger this heart condition? What you need to know about atrial fibrillation | Listen to this article
Can drinking cold water trigger this heart condition? What you need to know about atrial fibrillation
1 min
New: You can now listen to articles.
Sorry, the audio is unavailable right now. Please try again later.
This ... |
| 10.11.2023 | The first vaccine for the increasingly prevalent chikungunya virus is here | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we have two FDA approvals, preview late-breakers at this weekend’s American Heart Association scientific sessi... |
| 14.05.2021 | Setting the record straight: There is no ‘Covid heart’ | After a year of frightening headlines, widespread concern, and countless retweets that the virus that causes Covid-19 may attack the heart more aggressively than any other viral illness, the verdict is in: It doesn’t.
A report published las... |
| 30.06.2020 | How to address minority health inequities exposed during Covid-19 | The demonstrations against racial inequalities currently sweeping the globe, along with the continual spread of the coronavirus across the world, is shining a spotlight on an already serious problem the public health community has been figh... |
| 07.10.2019 | Report: Docs could reduce adverse events with Boston Sci’s Watchman | Boston Scientific’s Watchman FLX 2.0 (Image from Boston Scientific)
This article has been updated to include comments from Boston Scientific.
A recent review of FDA files has found nearly 3,000 adverse events related to Boston Scientific’s ... |
| 11.09.2017 | Abbott’s stent sales halt shows physicians didn’t buy into the next new, shiny object | Last week, Abbott Laboratories issued a statement on its website announcing it would halt the sales of its Absorb Bioresorbable Vascular Scaffold and Absorb GT1 Bioresorbable Vascular Scaffold system as of Sep. 14. The devices treat coronar... |
| 07.11.2016 | Vanishing stent vs durable stent wars continue | At the annual Transcatheter Cardiovascular Therapies conference last week in Washington, D.C., Abbott presented three-year data on its Absorb bioresorbable polymer stent that is used to open clogged arteries and elute everolimus. The device... |
| 17.09.2014 | Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup | Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the sma... |
| 16.09.2014 | TCT 2014 Roundup | Here’s a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
Abbott’s Absorb stent as good as Xience, maybe better for angina
One-year data on the Absorb stent ma... |
| 04.08.2014 | TAVI study: Sapien tops CoreValve in AR risk, but is CoreValve safer? | The results from a new registry study offered a mixed safety profile comparing Medtronic’s (NYSE:MDT) and Edwards Lifesciences’ (NYSE:EW) rival 1st-generation transcatheter aortic valve implantation systems.
Patients in the study who receiv... |
| 09.07.2014 | BioVentrix raises $12M for heart attack treatment | MassDevice.com On Call | MASSDEVICE ON CALL — BioVentrix reported a $12.4 million funding round for its Revivent heart failure treatment.
San Ramon, Calif.-based BioVentrix said in an equity filing that the equity round, involving 195 unnamed investors, began Jan. ... |
| 01.07.2014 | Study: Early CoreValve patients saw growing leakage, mortality risk | Patients who received Medtronic’s (NYSE:MDT) CoreValve implant in an early study saw a lot of benefits with the transcatheter aortic valve implantation system, but incidence of valve leakage and cardiovascular death marred 3-year outcomes.
... |
| 13.11.2013 | EXCLUSIVE: STJ Senior VP on three important changes to medical device industry in Asia | St. Jude Medical (STJ) has had a strong presence in Asia dating back to the medical device company’s creation of the first mechanical heart valve, STJ’s Senior Vice President in Asia and President of STJ Japan Bill Phillips said. In the pas... |
| 25.10.2012 | Heart valves: Three-year Sapien data buoy Edwards Lifesciences | Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation system, the only TAVI device on the U.S. market, demonstrated sustained and increasing survival benefits out to 3 years among inoperable heart failure patients, ... |
| 24.10.2012 | TAVI at TCT 2012: Climbing the learning curve and making way for improvement | TAVI registries showing greater success with experience, upgrades
As European clinics gain experience and new TAVI systems incorporate design improvements, the rates of procedure-related complications are sinking fast, according to registry... |
| 24.10.2012 | TCT 2012: Drug-eluting and semi-resorbable stents hold their own | Stent makers came out in force for the Transcatheter Cardiovascular Therapeutics meeting in Miami this week, touting results of clinical studies of next-generation drug-eluting stents and new designs with bioresorbable polymers.
Medtech ind... |
| 23.10.2012 | Stent wars at TCT 2012: Drug-eluting stents maintain lead over bare-metal | With new and next-generation stents gaining ground over their forebears, the stent wars don’t look to be letting up anytime soon.
The battle continued at the Transcatheter Cardiovascular Therapeutics meeting this week, where pooled results ... |
| 11.11.2011 | TCT 2011: Benefits for Edwards’ valve patients increase at the two-year mark | Patients treated with Edwards Lifesciences’ (NYSE:EW) Sapien heart valve had a lower mortality rate and spent less time in hospitals at the two-year mark, according to the data released at this year’s Transcatheter Cardiovascular Therapeuti... |
| 10.11.2011 | TCT 2011: Three ways to spur U.S. medical innovation | Dr. Martin Leon
The U.S. medical device arena is in danger of ceding the throne to countries with friendlier regulatory environments but the system is not irreparable, Dr. Martin Leon said during a lecture at this week’s Transcatheter Cardi... |
| 08.11.2011 | TCT 2011: Medtronic, Boston Scientific, Abbott continue the Stent Wars | The biggest names in interventional cardiology are in San Francisco this week for the Transcatheter Cardiovascular Therapeutics symposium, one of the Prime battlegrounds in the long-running stent wars between the likes of Boston Scientific ... |
| - | How to address minority health inequities exposed during Covid-19 | The demonstrations against racial inequalities currently sweeping the globe, along with the continual spread of the coronavirus across the world, is shining a spotlight on an already serious problem the public health community has been figh... |
| - | «На пять минут я ушел из этого мира». «МЮ» отдает ключевую роль Эриксену, перенесшему клиническую смерть | По информации британских медиа, Криштиану Роналду готов покинуть «Манчестер Юнайтед», поскольку ждал от клуба большей активности на трансферном рынке. Португалец надеялся увидеть в команде более пяти новых игроков, которые помогли бы вернут... |
| - | EXCLUSIVE: STJ Senior VP on three important changes to medical device industry in Asia | St. Jude Medical (STJ) has had a strong presence in Asia dating back to the medical device company’s creation of the first mechanical heart valve, STJ’s Senior Vice President in Asia and President of STJ Japan Bill Phillips said. In the pas... |
| - | Vanishing stent vs durable stent wars continue | The initial results are in and it doesn’t look that great for vanishing or bioresorbable cardiac stents that are designed to dissolve into a patients’ body over time compared with durable drug-eluting stents that leave an implant behind.
An... |
| - | Abbott’s stent sales halt shows physicians didn’t buy into the next new, shiny object | Last week, Abbott Laboratories issued a statement on its website announcing it would halt the sales of its Absorb Bioresorbable Vascular Scaffold and Absorb GT1 Bioresorbable Vascular Scaffold system as of Sep. 14. The devices treat coronar... |
